SHANGHAI LABWAY CLINICAL LABORATORY CO., LTD Shanghai Labway Clinical Laboratory Co., Ltd Share Price
Equities
301060
CNE100004RG8
Healthcare Facilities & Services
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.77 CNY | -0.20% |
|
+8.19% | -26.49% |
| Sales 2022 | 4.2B 580M 48.32B | Sales 2023 | 1.67B 231M 19.27B | Capitalization | 5.32B 735M 61.25B |
|---|---|---|---|---|---|
| Net income 2022 | 617M 85.15M 7.1B | Net income 2023 | -142M -19.6M -1.63B | EV / Sales 2022 | 1.77 x |
| Net cash position 2022 | 421M 58.13M 4.85B | Net cash position 2023 * | - 0 0 | EV / Sales 2023 | 3.18 x |
| P/E ratio 2022 |
12.7
x | P/E ratio 2023 |
-37.6
x | Employees | 1,878 |
| Yield 2022 |
1.53% | Yield 2023 |
-
| Free-Float | 32.29% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.20% | ||
| 1 week | +8.19% | ||
| Current month | -18.24% | ||
| 1 month | -15.85% | ||
| 3 months | -13.54% | ||
| 6 months | -26.93% | ||
| Current year | -26.49% |
1 week
8.79
9.95
1 month
8.6212.43
Current year
7.3414.77
1 year
7.3420.75
3 years
7.3461.20
5 years
7.3461.20
10 years
7.3461.20
| Managers | Title | Age | Since |
|---|---|---|---|
Wei Xiong Zeng
CEO | Chief Executive Officer | 56 | 20/15/20 |
Xi Gu Wang
DFI | Director of Finance/CFO | 54 | 22/22/22 |
Zhi Sen Mao
BRD | Director/Board Member | 64 | 17/21/17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Lei Wang
BRD | Director/Board Member | 42 | 17/21/17 |
Zhi Hua He
BRD | Director/Board Member | 61 | 20/15/20 |
Wei Xiong Zeng
CEO | Chief Executive Officer | 56 | 20/15/20 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.07% | 12 M€ | -16.71% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 9.77 | -0.20% | 5,898,500 |
| 25/24/25 | 9.79 | +1.14% | 5,012,100 |
| 24/24/24 | 9.68 | +2.65% | 6,221,600 |
| 23/24/23 | 9.43 | +3.63% | 6,003,200 |
| 22/24/22 | 9.1 | +0.78% | 4,534,926 |
End-of-day quote Shenzhen S.E., April 26, 2024
More quotes
Shanghai Labway Clinical Laboratory Co Ltd is a company providing overall solutions for the inspection and diagnosis industry. The Company's businesses include medical testing and pathological diagnosis services and the sales of in vitro diagnosis product. The medical examination and pathological diagnosis services include pathological diagnosis, molecular examination, biochemical examination, immune examination, microbial examination, clinical basic examination and physical and chemical examination. The in vitro diagnostic products sales include in vitro diagnostic instruments, reagents and related accessories and consumables.
Calendar
23/08/2024
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -26.49% | 540M | |
| -17.89% | 8.25B | |
| +39.20% | 3.58B | |
| -39.11% | 2.46B | |
| -8.06% | 2.46B | |
| -7.35% | 2.38B | |
| -12.61% | 1.81B | |
| -19.01% | 1.55B | |
| -40.66% | 1.21B | |
| +7.56% | 1.11B |
- Stock Market
- Equities
- 301060 Stock
